Apogee Therapeutics, Inc. Common Stock • APGE

Capital at risk.

About Apogee Therapeutics, Inc. Common Stock
Ticker
info
APGE
Trading on
info
NASDAQ
ISIN
info
US03770N1019
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Michael Thomas Henderson M.D.
Headquarters
info
One Letterman Drive, San Francisco, CA, United States, 94129-1492
Employees
info
261
Website
info
apogeetherapeutics.com
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.
Metrics
BasicAdvanced
Market cap
info
$10.2B
P/E ratio
info
-
EPS
info
-$4.34
Dividend Yield
info
0.00%
Beta
info
0.33
Forward P/E ratio
info
0
EBIDTA
info
$-322M
Ex dividend date
info
-
Price & volume
Market cap
info
$10.2B
Average daily volume
info
0.9M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
0
Price to book
info
8.56
Earnings
EPS
info
-$4.34
EPS estimate (current quarter)
info
-$0.96
EPS estimate (next quarter)
info
-$1.29
EBITDA
info
$-322M
Revenues (TTM)
info
$0M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
0.33
52-week High
info
$135.09
52-week Low
info
$35.39
50-day moving average
info
$134.18
200-day moving average
info
$93.12
Short ratio
info
3.63
Short %
info
7.28%
Management effectiveness
ROE (TTM)
info
-32.46%
ROA (TTM)
info
-20.30%
Profit margin
info
0.00%
Gross profit margin
info
$0M
Operating margin
info
0.00%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
62.2M
Float
info
58.4M
Insiders %
info
2.32%
Institutions %
info
110.81%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 9 analysts.

Average price target

info
$134.62
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$1.11
-$1.15
3.48%
Q3 • 25Beat
-$1.03
-$0.62
-66.13%
Q4 • 25Missed
-$1.06
-$1.13
6.19%
Q1 • 26Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$-74.1M
-∞%
Q1 • 26
$0M
$-85.9M
-∞%
Q2 • 26
NaN%
15.85%
NaN%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$1.29B
$37.9M
2.93%
Q1 • 26
$1.34B
$141M
10.57%
Q2 • 26
3.26%
272.97%
261.20%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-55.6M
$-35.3M
$411M
$-55.6M
Q1 • 26
$-71.4M
$-382M
$107M
$-71.4M
Q2 • 26
28.45%
980.28%
-73.97%
28.45%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Apogee Therapeutics, Inc. Common Stock share?
Collapse

Apogee Therapeutics, Inc. Common Stock shares are currently traded for undefined per share.

How many shares does Apogee Therapeutics, Inc. Common Stock have?
Collapse

Apogee Therapeutics, Inc. Common Stock currently has 62.2M shares.

Does Apogee Therapeutics, Inc. Common Stock pay dividends?
Collapse

No, Apogee Therapeutics, Inc. Common Stock doesn't pay dividends.

What is Apogee Therapeutics, Inc. Common Stock 52 week high?
Collapse

Apogee Therapeutics, Inc. Common Stock 52 week high is $135.09.

What is Apogee Therapeutics, Inc. Common Stock 52 week low?
Collapse

Apogee Therapeutics, Inc. Common Stock 52 week low is $35.39.

What is the 200-day moving average of Apogee Therapeutics, Inc. Common Stock?
Collapse

Apogee Therapeutics, Inc. Common Stock 200-day moving average is $93.12.

Who is Apogee Therapeutics, Inc. Common Stock CEO?
Collapse

The CEO of Apogee Therapeutics, Inc. Common Stock is Dr. Michael Thomas Henderson M.D..

How many employees Apogee Therapeutics, Inc. Common Stock has?
Collapse

Apogee Therapeutics, Inc. Common Stock has 261 employees.

What is the market cap of Apogee Therapeutics, Inc. Common Stock?
Collapse

The market cap of Apogee Therapeutics, Inc. Common Stock is $10.2B.

What is the P/E of Apogee Therapeutics, Inc. Common Stock?
Collapse

The current P/E of Apogee Therapeutics, Inc. Common Stock is null.

What is the EPS of Apogee Therapeutics, Inc. Common Stock?
Collapse

The EPS of Apogee Therapeutics, Inc. Common Stock is -$4.34.

What is the PEG Ratio of Apogee Therapeutics, Inc. Common Stock?
Collapse

The PEG Ratio of Apogee Therapeutics, Inc. Common Stock is null.

What do analysts say about Apogee Therapeutics, Inc. Common Stock?
Collapse

According to the analysts Apogee Therapeutics, Inc. Common Stock is considered a buy.